get a key
steadybase-$ company ALVO
account_id none on file
legal_name Alvotech
ticker ALVO
cik 1898416
domain alvotech.com
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
calls 0 filings 62 executives 0 family 0
why_nownone on file
callsnone on file
filings
Linda Jónsdóttir has served as our Chief Financial Officer since July 2025. Prior to joining Alvotech, she held senior roles for 15 years at Marel, a global leader in food processing technology, including Director of Treasury and Investor Relations, Chief Financial Officer and Chief Operating Officer, until stepping down in 2024.

filing / Mar 31, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may therefore prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.

filing / Mar 31, 2026 / receipt

Cost savings generated by biosimilars can be used to treat more people and to sustain the cost of investment in the next generations of innovative therapies.

filing / Mar 31, 2026 / receipt

This amount reflects the financial impact of the extinguishment of the second tranche and certain lenders of the first tranche, as well as the modification of terms under the consolidated Facility, which now bears interest at SOFR plus 6.0 % per annum.

filing / Mar 31, 2026 / receipt

Additionally, by partnering with multiple partners, we are able to enhance local market knowledge and expand our geographic reach by mitigating our risk of being dependent on one single partner.

filing / Mar 31, 2026 / receipt

In addition, because of the hybrid work policies we implemented, information that is normally protected, including company confidential information, may be less secure.

filing / Mar 31, 2026 / receipt

Global commercialization Expanding patient access through our partner network worldwide

ir_statement / Sep 15, 2026 / receipt

Product launches Commercialization of newly approved and upcoming products

ir_statement / Sep 15, 2026 / receipt

$0.6m cost related to workforce optimization and organizational realignment

ir_statement / Sep 15, 2026 / receipt

$2.1m cost related to workforce optimization and organizational realignment

ir_statement / Sep 15, 2026 / receipt

AVT05 and AVT06 launched in >10 European markets

ir_statement / Sep 15, 2026 / receipt

New launches expanding presence in Japan

ir_statement / Sep 15, 2026 / receipt

executivesnone on file
familynone on file
upcoming
2026-11-11 earnings call scheduled webcast / ir
changesnone on file
mcp_package_hint
steadybase-$